Sionna Therapeutics (NASDAQ:SION) Trading Down 10.1% – Time to Sell?

Shares of Sionna Therapeutics, Inc. (NASDAQ:SION) fell 10.1% during mid-day trading on Monday . The stock traded as low as $35.29 and last traded at $35.29. 28,699 shares changed hands during mid-day trading, a decline of 91% from the average session volume of 314,592 shares. The stock had previously closed at $39.25.

Analyst Upgrades and Downgrades

SION has been the topic of several analyst reports. Raymond James Financial reiterated a “strong-buy” rating and set a $53.00 target price on shares of Sionna Therapeutics in a report on Monday, January 5th. Lifesci Capital assumed coverage on shares of Sionna Therapeutics in a report on Tuesday, December 23rd. They set an “outperform” rating and a $60.00 target price on the stock. BTIG Research reaffirmed a “buy” rating and set a $58.00 price target on shares of Sionna Therapeutics in a research report on Wednesday. Royal Bank Of Canada reissued an “underperform” rating and issued a $24.00 price objective on shares of Sionna Therapeutics in a research report on Monday, December 1st. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Sionna Therapeutics in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $45.43.

Sionna Therapeutics Stock Performance

The stock has a market capitalization of $1.84 billion and a price-to-earnings ratio of -8.46. The business has a fifty day simple moving average of $40.58 and a 200 day simple moving average of $30.50.

Sionna Therapeutics (NASDAQ:SION) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.06.

Insider Buying and Selling

In related news, Director Orbimed Advisors Llc sold 94,583 shares of the business’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $44.54, for a total value of $4,212,726.82. Following the completion of the transaction, the director owned 3,610,376 shares of the company’s stock, valued at $160,806,147.04. The trade was a 2.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Peter A. Thompson sold 94,583 shares of the stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $44.54, for a total transaction of $4,212,726.82. Following the sale, the director owned 3,610,376 shares in the company, valued at $160,806,147.04. The trade was a 2.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 1,312,357 shares of company stock valued at $50,469,863 in the last ninety days. Insiders own 3.90% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Russell Investments Group Ltd. bought a new stake in shares of Sionna Therapeutics during the 3rd quarter valued at approximately $30,000. BNP Paribas Financial Markets acquired a new stake in Sionna Therapeutics in the second quarter valued at approximately $31,000. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Sionna Therapeutics during the second quarter worth $45,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Sionna Therapeutics during the third quarter worth $147,000. Finally, Virtus Investment Advisers LLC acquired a new position in shares of Sionna Therapeutics during the second quarter worth $96,000.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.